| Dr Lawrence L Bushkell Jr, MD | |
|
2018 Western Ave, Knoxville, TN 37921-5718 | |
| (865) 544-0406 | |
| (865) 544-0480 |
| Full Name | Dr Lawrence L Bushkell Jr |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 54 Years |
| Location | 2018 Western Ave, Knoxville, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376501544 | NPI | - | NPPES |
| 3376258 | Medicaid | TN | |
| 0015500 | Other | TN | BLUE CROSS |
| 4034509 | Other | TN | AETNA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ND0101X | Dermatology - Mohs-micrographic Surgery | 13438 (Tennessee) | Secondary |
| 207N00000X | Dermatology | 13438 (Tennessee) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cherokee Health Systems | 3577474295 | 99 |
News Archive
CDEX Inc. and All Business Machines, Inc. announce that the ValiMed™ MVS (Medication Validation System) and ID2 Meth Scanner™ product lines by CDEX have been placed on the ABMI GSA Contract Schedule. ValiMed MVS puts a technological safety net between the patient and errors made in the compounding of high risk medications and guards against narcotic diversion. Both are now available to the Government markets through the ABMI GSA Schedule.
Fate Therapeutics, Inc. announced today promising clinical results from a Phase 1b trial of ProHema (FT1050-enhanced umbilical cord blood) as part of double-umbilical cord blood (UCB) transplants in adult patients with hematologic malignancies who have undergone reduced-intensity conditioning therapy.
A new study by Lyle Hood, assistant professor of mechanical engineering at The University of Texas at San Antonio, describes a new device that could revolutionize the delivery of medicine to treat cancer as well as a host of other diseases and ailments.
Researchers are one step closer to providing a new therapy for colon cancer, after findings revealed that a small molecule focal adhesion kinase (FAK) inhibitor known as Y15 effectively blocked cell viability, promoted detachment and apoptosis, and decreased tumor growth in mice. These findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.
› Verified 2 days ago
| Entity Name | Cherokee Health Systems |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134128820 PECOS PAC ID: 3577474295 Enrollment ID: O20031119000769 |
News Archive
CDEX Inc. and All Business Machines, Inc. announce that the ValiMed™ MVS (Medication Validation System) and ID2 Meth Scanner™ product lines by CDEX have been placed on the ABMI GSA Contract Schedule. ValiMed MVS puts a technological safety net between the patient and errors made in the compounding of high risk medications and guards against narcotic diversion. Both are now available to the Government markets through the ABMI GSA Schedule.
Fate Therapeutics, Inc. announced today promising clinical results from a Phase 1b trial of ProHema (FT1050-enhanced umbilical cord blood) as part of double-umbilical cord blood (UCB) transplants in adult patients with hematologic malignancies who have undergone reduced-intensity conditioning therapy.
A new study by Lyle Hood, assistant professor of mechanical engineering at The University of Texas at San Antonio, describes a new device that could revolutionize the delivery of medicine to treat cancer as well as a host of other diseases and ailments.
Researchers are one step closer to providing a new therapy for colon cancer, after findings revealed that a small molecule focal adhesion kinase (FAK) inhibitor known as Y15 effectively blocked cell viability, promoted detachment and apoptosis, and decreased tumor growth in mice. These findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lawrence L Bushkell Jr, MD 1923 Sulphur Springs Rd, Morristown, TN 37813-5654 Ph: (423) 317-9344 | Dr Lawrence L Bushkell Jr, MD 2018 Western Ave, Knoxville, TN 37921-5718 Ph: (865) 544-0406 |
News Archive
CDEX Inc. and All Business Machines, Inc. announce that the ValiMed™ MVS (Medication Validation System) and ID2 Meth Scanner™ product lines by CDEX have been placed on the ABMI GSA Contract Schedule. ValiMed MVS puts a technological safety net between the patient and errors made in the compounding of high risk medications and guards against narcotic diversion. Both are now available to the Government markets through the ABMI GSA Schedule.
Fate Therapeutics, Inc. announced today promising clinical results from a Phase 1b trial of ProHema (FT1050-enhanced umbilical cord blood) as part of double-umbilical cord blood (UCB) transplants in adult patients with hematologic malignancies who have undergone reduced-intensity conditioning therapy.
A new study by Lyle Hood, assistant professor of mechanical engineering at The University of Texas at San Antonio, describes a new device that could revolutionize the delivery of medicine to treat cancer as well as a host of other diseases and ailments.
Researchers are one step closer to providing a new therapy for colon cancer, after findings revealed that a small molecule focal adhesion kinase (FAK) inhibitor known as Y15 effectively blocked cell viability, promoted detachment and apoptosis, and decreased tumor growth in mice. These findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.
› Verified 2 days ago
Dr. Drew Wilson Miller, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1928 Alcoa Hwy, Ste 209, Knoxville, TN 37920 Phone: 865-524-2547 Fax: 865-219-5070 | |
Dr. Matthew C Hanggi, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 123 Fox Rd, Knoxville, TN 37922 Phone: 865-690-9467 Fax: 865-637-5057 | |
Elizabeth Brittian Anderson, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 6516 Kingston Pike, Knoxville, TN 37919 Phone: 865-450-9361 Fax: 865-450-9362 | |
Sandra Vaughn, NP Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1928 Alcoa Hwy Ste 209, Knoxville, TN 37920 Phone: 865-524-2547 Fax: 865-524-0224 | |
Anne Elizabeth Allen, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 6516 Kingston Pike, Knoxville, TN 37919 Phone: 865-450-9361 | |
Mr. Marcus Rene Ortiz Jr., PA-C Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1450 Dowell Springs Blvd Ste 210, Knoxville, TN 37909 Phone: 865-524-2547 Fax: 865-205-5601 | |
Dr. Edward John Primka Iii, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1450 Dowell Springs Blvd Ste 210, Knoxville, TN 37909 Phone: 865-524-2547 Fax: 865-205-5601 |